Blog
RSS FeedPosted by Michael Wonder on 31 Jan 2024
Loncastuximab tesirine for treating relapsed or refractory diffuse large B-cell lymphoma and high-grade B-cell lymphoma after 2 or more systemic treatments
31 January 2024 - NICE has published evidence-based recommendations on the use of loncastuximab tesirine (Zynlonta) for the treatment of ...
Posted by Michael Wonder on 30 Jan 2024
Treosulphan in combination with fludarabine phosphate before allogeneic stem cell transplantation for patients aged 1 month to 17 years with non-malignant diseases
30 January 2024 - NICE is unable to make a recommendation on the use of treosulphan (Trecondi) in combination with fludarabine ...
Posted by Michael Wonder on 19 Jan 2024
300 people to benefit from new treatment for advanced breast cancer recommended by NICE following price deal
19 January 2024 - Around 300 people are set to benefit following NICE’s recommendation of talazoparib tosylate for treating a type ...
Posted by Michael Wonder on 17 Jan 2024
Olaparib in combination with bevacizumab for the maintenance treatment of adults with advanced high grade epithelial ovarian, fallopian tube or primary peritoneal cancer
17 January 2024 - NICE has published evidence-based recommendations on the use of olaparib (Lynparza) in combination with bevacizumab (Avastin) ...
Posted by Michael Wonder on 15 Jan 2024
Durvalumab with cisplatin and gemcitabine hydrochloride for the treatment of patients with unresectable or advanced biliary tract cancer
10 January 2024 - NICE has published evidence-based recommendations on the use of durvalumab (Imfinzi) in combination with cisplatin and ...
Posted by Michael Wonder on 13 Dec 2023
Pembrolizumab and chemotherapy with or without bevacizumab for patients with persistent, recurrent or metastatic cervical cancer
13 December 2023 - NICE has published final evidence-based recommendations on the use of pembrolizumab (Keytruda) and chemotherapy with or ...
Posted by Michael Wonder on 01 Dec 2023
Pembrolizumab with trastuzumab and chemotherapy for the first-line treatment of patients with advanced HER2 positive gastric or gastro-oesophageal junction cancer
1 December 2023 - The Department of Health and Social Care has asked NICE to produce guidance on the use ...
Posted by Michael Wonder on 30 Nov 2023
Cabozantinib maleate with nivolumab for patients with untreated advanced renal cell carcinoma
30 November 2023 - The Department of Health and Social Care has asked NICE to produce guidance on the use ...
Posted by Michael Wonder on 30 Nov 2023
Idecabtagene vicleucel for the treatment of patients with relapsed and refractory multiple myeloma after 3 or more treatments
30 November 2023 - NICE is unable to make a recommendation on the use of idecabtagene vicleucel (Abecma) for the treatment ...
Posted by Michael Wonder on 29 Nov 2023
Belzutifan for the treatment of patients with a tumour associated with von Hippel-Lindau disease
29 November 2023 - The Department of Health and Social Care has asked NICE to produce guidance on the use ...
Posted by Michael Wonder on 29 Nov 2023
Tisagenlecleucel for the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic therapies
29 November 2023 - NICE is unable to make a recommendation on the use of tisagenlecleucel (Kymriah) for the treatment of ...
Posted by Michael Wonder on 23 Nov 2023
Cedazuridine with decitabine for patients with untreated acute myeloid leukaemia when intensive chemotherapy is unsuitable
23 November 2023 - NICE is unable to make a recommendation on the use of cedazuridine with decitabine (Inaqovi) for the ...
Posted by Michael Wonder on 22 Nov 2023
Zanubrutinib for the treatment of patients with chronic lymphocytic leukaemia (final guidance)
22 November 2023 - NICE has published final evidence-based recommendations on the use of zanubrutinib (Brukinsa) for the treatment of ...
Posted by Michael Wonder on 15 Nov 2023
Lutetium Lu 177 vipivotide tetraxetan for the treatment of patients with metastatic PSMA positive hormone-relapsed prostate cancer after two or more treatments
15 November 2023 - NICE has published final evidence-based recommendations on the use of lutetium Lu 177 vipivotide tetraxetan (Pluvicto) ...
Posted by Michael Wonder on 02 Nov 2023
Ivosidenib for the treatment of patients with advanced IDH1 mutation positive cholangiocarcinoma after at least one line of treatment
2 November 2023 - The Department of Health and Social Care has asked NICE to produce guidance on the use ...